Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Current Assets (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Current Assets data on record, last reported at $1.0 billion in Q1 2025.

  • For Q1 2025, Current Assets changed N/A year-over-year to $1.0 billion; the TTM value through Mar 2025 reached $1.0 billion, changed N/A, while the annual FY2023 figure was $831.0 million, 22.12% down from the prior year.
  • Current Assets reached $1.0 billion in Q1 2025 per RCUS's latest filing, up from $1.0 billion in the prior quarter.
  • Across five years, Current Assets topped out at $1.3 billion in Q1 2022 and bottomed at $545.3 million in Q3 2021.
  • Average Current Assets over 5 years is $987.3 million, with a median of $1.0 billion recorded in 2023.
  • The widest YoY moves for Current Assets: up 406.49% in 2021, down 31.6% in 2021.
  • A 5-year view of Current Assets shows it stood at $1.3 billion in 2021, then fell by 15.45% to $1.1 billion in 2022, then decreased by 22.12% to $831.0 million in 2023, then rose by 22.98% to $1.0 billion in 2024, then grew by 0.88% to $1.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $1.0 billion in Q1 2025, $1.0 billion in Q2 2024, and $831.0 million in Q4 2023.